CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/04/25
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewsWire • 10/30/25
CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025GlobeNewsWire • 07/31/25
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic MelanomaGlobeNewsWire • 05/19/25
CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)Seeking Alpha • 05/12/25
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/12/25
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockGlobeNewsWire • 05/12/25
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)GlobeNewsWire • 05/12/25
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/25